drugset
drugset / Trial / NCT06871527

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

NCT06871527 ↗

Phase 1/2 Not yet recruiting 44 enrolled Sixth Affiliated Hospital, Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Timeline

Start
2025-03-01
Primary completion
2028-03-30
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 3 mg Oral
Subject Fruquintinib Small molecule 4 mg Oral
Subject Fruquintinib Small molecule 5 mg Oral
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Tislelizumab Monoclonal antibody 200 mg Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

gastric adenocarcinoma gastroesophageal junction adenocarcinoma